Present and Future in the Treatment of Diabetic Kidney Disease
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Diabetic kidney disease is the leading cause of end-stage renal disease. Albuminuria is recognized as the most important prognostic factor for chronic kidney disease progression. For this reason, blockade of renin-angiotensin system remains the main recommended strategy, with either angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. However, other antiproteinuric treatments have begun to be studied, such as direct renin inhibitors or aldosterone blockers. Beyond antiproteinuric treatments, other drugs such as pentoxifylline or bardoxolone have yielded conflicting results. Finally, alternative pathogenic pathways are being explored, and emerging therapies including antifibrotic agents, endothelin receptor antagonists, or transcription factors show promising results. The aim of this review is to explain the advances in newer agents to treat diabetic kidney disease, along with the background of the renin-angiotensin system blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598 · cited 2×
“In the ROADMAP trial, proteinuria had a delayed onset in those patients treated with olmesartan, although at the expense of higher rates of cardiovascular events [23].”
BackgroundTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502 · cited 3×
“While using ARB or ACEI to lower proteinuria in DKD and in proteinuric CKD is considered mandatory (evidence grade 1A), the lack of positive studies has encouraged a change in current recommendations against the use of dual blockade [41–43].”
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Risk Factors for Renal Dysfunction in Type 2 Diabetes
Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I., Holman, R. R., & for the UKPDS Study Group (2006) · Diabetes · doi:10.2337/db05-1620 · Cited by 927
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
Haller, H., Ito, S., Izzo, J. L., Januszewicz, A., Katayama, S., Menne, J., Mimran, A., Rabelink, T. J., Ritz, E., Ruilope, L. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007994 · Cited by 792
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694 · cited 1×
“[10] DCCT/EDIC Research Group, “Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial,” Kidney International, vol.”
MethodIntensive diabetes therapy and glomerular filtration rate in type 1 diabetes
The DCCT/EDIC Research Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1111732 · Cited by 568
Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy
Zheng, H., Whitman, S. A., Wu, W., Wondrak, G. T., Wong, P. K., Fang, D., & Zhang, D. D. (2011) · Diabetes · doi:10.2337/db11-0807 · Cited by 507
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466 · cited 2×
“[47] 55 (spironolactone 25mg/day to those patients with aldosterone escape after ACEI) Early stage of CKD (eGFR >60mL/min/1.”
BackgroundKasiske, B., Lakatua, J., Ma, J., & Louis, T. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9631839 · Cited by 408
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International · doi:10.1038/ki.2012.401 · Cited by 316
Molitch, M. E., Steffes, M., Sun, W., Rutledge, B., Cleary, P., de Boer, I. H., Zinman, B., Lachin, J., & for the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1098 · Cited by 306
de Boer, I. H., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2113 · Cited by 254 · cited 2×
“This effect has been proved valid in both type 1 and type 2 DKD and in the short and long terms [10–16].”
BackgroundLong-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice
Flyvbjerg, A., Denner, L., Schrijvers, B. F., Tilton, R. G., Mogensen, T. H., Paludan, S. R., & Rasch, R. (2004) · Diabetes · doi:10.2337/diabetes.53.1.166 · Cited by 187
Rodriguez-Vita, J., Ruiz-Ortega, M., Rupérez, M., Esteban, V., Sanchez-López, E., Plaza, J. J., & Egido, J. (2005) · Circulation Research · doi:10.1161/01.res.0000174614.74469.83 · Cited by 119
Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats
Moriwaki, Y., Inokuchi, T., Yamamoto, A., Ka, T., Tsutsumi, Z., Takahashi, S., & Yamamoto, T. (2007) · Acta Diabetologica · doi:10.1007/s00592-007-0007-6 · Cited by 110
Bhattacharya, S., Manna, P., Gachhui, R., & Sil, P. C. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.12.005 · Cited by 83
Takahashi, T., Yano, M., Minami, J., Haraguchi, T., Koga, N., Higashi, K., & Kobori, S. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00105-5 · Cited by 72 · cited 1×
“On the other hand, serotonin has also been studied, and 5-hydroxytryptamine receptor antagonist sarpogrelate, which is more known for its antiplatelet action, has also demonstrated renal anti-inflammatory and antiproteinuric effects [122, 123] and is undergoing a phase IV randomized control trial.”
Background
Cited by
Macrophages: versatile players in renal inflammation and fibrosis
Tang, P. M.-K., Nikolic-Paterson, D. J., & Lan, H.-Y. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0110-2 · Cited by 1,033
Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment
Samsu, N. (2021) · BioMed Research International · doi:10.1155/2021/1497449 · Cited by 1,001
Lv, W., Booz, G. W., Wang, Y., Fan, F., & Roman, R. J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.12.016 · Cited by 338
Insights into predicting diabetic nephropathy using urinary biomarkers
Khan, N. U., Lin, J., Liu, X., Li, H., Lu, W., Zhong, Z., Zhang, H., Waqas, M., & Shen, L. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140475 · Cited by 90
Metadata
- Authors
- Quiroga, B., Arroyo, D., & de Arriba, G.
- Venue
- Journal of Diabetes Research
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-13
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- OpenAlex
- W1996228192
- Cited by
- 40
- References
- 24
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.